neuroleptic malignant syndrome

Summary

Summary: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Top Publications

  1. ncbi Lethal catatonia
    Vladan Ljubisavljevic
    Aust N Z J Psychiatry 36:563-4. 2002
  2. ncbi Neuroleptic malignant syndrome and atypical antipsychotic drugs
    Jambur Ananth
    University of California, Los Angeles, CA, USA
    J Clin Psychiatry 65:464-70. 2004
  3. ncbi Comments on the report of neuroleptic malignant syndrome induced by ziprasidone
    Branimir Margetic
    World J Biol Psychiatry 8:131-2; author reply 133-4. 2007
  4. ncbi Neuroleptic malignant syndrome
    Jeffrey R Strawn
    University of Cincinnati, Department of Psychiatry, College of Medicine, Box 670559, Cincinnati, OH 45267-0559, USA
    Am J Psychiatry 164:870-6. 2007
  5. ncbi Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome
    Feriha Ozer
    Department of Neurology, Bakirkoy Neurology Center, Istanbul, Turkey
    J ECT 21:125-7. 2005
  6. ncbi Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol
    Cassandra J Bellamy
    Department of Pharmacy, Medical Intensive Care Unit, Hospital of University of Pennsylvania, USA
    J Trauma 66:954-8. 2009
  7. ncbi The evaluation and management of patients with neuroleptic malignant syndrome
    Minal J Bhanushali
    Department of Neurology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Neurol Clin 22:389-411. 2004
  8. ncbi Successful treatment of a complicated case of neuroleptic malignant syndrome
    A Lappa
    Intensive Care Unit, M G Vannini Hospital, Via A Bullicante no 4, 00177 Rome, Italy
    Intensive Care Med 28:976-7. 2002
  9. ncbi The WHO analgesic ladder and neuroleptic malignant syndrome
    Y Asakura
    Acta Anaesthesiol Scand 50:1311-2. 2006
  10. ncbi An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method
    Ronald J Gurrera
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Psychiatry 72:1222-8. 2011

Research Grants

  1. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
  2. Ecstasy and the Dorsomedial Hypothalamus
    DANIEL RUSYNIAK; Fiscal Year: 2007
  3. Multidisciplinary Study of Social Behavior and Emotion in Frontotemporal Dementia
    Mario Mendez; Fiscal Year: 2009
  4. Multidisciplinary Study of Social Behavior and Emotion in Frontotemporal Dementia
    MARIO FERNANDO MENDEZ; Fiscal Year: 2010
  5. CNS circuitry and receptors mediating the effects of MDMA
    Daniel E Rusyniak; Fiscal Year: 2010

Detail Information

Publications208 found, 100 shown here

  1. ncbi Lethal catatonia
    Vladan Ljubisavljevic
    Aust N Z J Psychiatry 36:563-4. 2002
  2. ncbi Neuroleptic malignant syndrome and atypical antipsychotic drugs
    Jambur Ananth
    University of California, Los Angeles, CA, USA
    J Clin Psychiatry 65:464-70. 2004
    OBJECTIVE: The incidence of neuroleptic malignant syndrome (NMS) is not known, but the frequency of its occurrence with conventional antipsychotic agents has been reported to vary from 0.02% to 2.44%...
  3. ncbi Comments on the report of neuroleptic malignant syndrome induced by ziprasidone
    Branimir Margetic
    World J Biol Psychiatry 8:131-2; author reply 133-4. 2007
  4. ncbi Neuroleptic malignant syndrome
    Jeffrey R Strawn
    University of Cincinnati, Department of Psychiatry, College of Medicine, Box 670559, Cincinnati, OH 45267-0559, USA
    Am J Psychiatry 164:870-6. 2007
  5. ncbi Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome
    Feriha Ozer
    Department of Neurology, Bakirkoy Neurology Center, Istanbul, Turkey
    J ECT 21:125-7. 2005
    ..A patient with Parkinson disease, major depression, and paranoid psychosis who developed neuroleptic malignant syndrome (NMS) as the result of the sudden termination of high-dose (1200 mg/d) levodopa treatment is presented ..
  6. ncbi Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol
    Cassandra J Bellamy
    Department of Pharmacy, Medical Intensive Care Unit, Hospital of University of Pennsylvania, USA
    J Trauma 66:954-8. 2009
    ..used to treat agitation in critically ill patients, has been associated with the development of neuroleptic malignant syndrome (NMS)...
  7. ncbi The evaluation and management of patients with neuroleptic malignant syndrome
    Minal J Bhanushali
    Department of Neurology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Neurol Clin 22:389-411. 2004
    ..Definitive treatment guidelines remain an important issue to be addressed. Efforts have been initiated in that direction and all cases can be reported on a toll-free hotline ( 1-888-667-8367) or online (www.nmsis.org)...
  8. ncbi Successful treatment of a complicated case of neuroleptic malignant syndrome
    A Lappa
    Intensive Care Unit, M G Vannini Hospital, Via A Bullicante no 4, 00177 Rome, Italy
    Intensive Care Med 28:976-7. 2002
    b>Neuroleptic malignant syndrome (NMS) is a life-threatening reaction often related to neuroleptic drugs, characterized by rigidity, hyperthermia, altered consciousness, and fluctuating blood pressure...
  9. ncbi The WHO analgesic ladder and neuroleptic malignant syndrome
    Y Asakura
    Acta Anaesthesiol Scand 50:1311-2. 2006
  10. ncbi An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method
    Ronald J Gurrera
    Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Psychiatry 72:1222-8. 2011
    The lack of generally accepted diagnostic criteria for neuroleptic malignant syndrome (NMS) impedes research and clinical management of patients receiving antipsychotic medications...
  11. ncbi Early recognition of neuroleptic malignant syndrome during traumatic brain injury rehabilitation
    Vivek Kadyan
    Department of Physical Medicine and Rehabilitation, The Ohio State University Medical Center, Columbus, OH, USA
    Brain Inj 17:631-7. 2003
    b>Neuroleptic malignant syndrome is a rare disorder that manifests with hyperthermia, muscle rigidity and autonomic instability...
  12. ncbi Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report
    Rhonda Malyuk
    Department of Pharmacy, Riverview Hospital, Port Coquitlam, BC, Canada
    Int J Geriatr Psychiatry 17:326-8. 2002
    We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history...
  13. ncbi Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome
    Jui Hsiu Tsai
    Department of Psychiatry, Kaohsiung Medical University Hsiaokang Hospital, Kaohsiung, Taiwan
    Pharmacotherapy 25:1156-9. 2005
    ..b>Neuroleptic malignant syndrome (NMS) was diagnosed...
  14. ncbi Olanzapine-associated neuroleptic malignant syndrome
    Nick B Norgard
    Department of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma 73117 5040, USA
    Pharmacotherapy 26:1180-2. 2006
    b>Neuroleptic malignant syndrome (NMS) is a rare but potentially serious complication of neuroleptic drugs. It may vary in both presenting characteristics and severity...
  15. ncbi Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome
    Rachel E Dew
    Department of Psychiatry, Wake Forest University Baptist Medical Center, Winston Salem, NC 27157, USA
    Int J Adolesc Med Health 17:187-8. 2005
    b>Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic.
  16. ncbi Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents
    Gil Zalsman
    Adolescence Inpatient Unit, Geha Psychiatric Hospital, Petach Tiqva, Israel
    Int J Adolesc Med Health 16:179-82. 2004
    b>Neuroleptic Malignant Syndrome (NMS) is a known, life threatening, side effect of classical antipsychotic drugs...
  17. ncbi Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome
    Sebahattin Vurucu
    Department of Pediatrics, Gulhane Military Medical Academy, Ankara, Turkey
    J Natl Med Assoc 101:273-5. 2009
    ..b>Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs, in which the ..
  18. ncbi Neuroleptic malignant syndrome associated with atypical antipsychotic drugs
    Julian N Trollor
    School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia
    CNS Drugs 23:477-92. 2009
    b>Neuroleptic malignant syndrome (NMS) is a rare but potentially severe idiosyncratic adverse reaction usually seen in the context of treatment with antipsychotic drugs...
  19. ncbi Neuroleptic malignant syndrome without neuroleptics
    K C Ong
    Department of Respiratory and Critical Care Medicine, Singapore General Hospital
    Singapore Med J 42:85-8. 2001
    b>Neuroleptic malignant syndrome is an uncommon condition characterised by hyperthermia, rigidity, altered mentation and autonomic instability...
  20. ncbi Catatonia is a risk factor for neuroleptic malignant syndrome
    Brendan T Carroll
    J Clin Psychiatry 65:1722-3. 2004
  21. ncbi Neuroleptic malignant syndrome and catatonia. A report of three cases
    M Raja
    Ospedale Santo Spirito, Dipartimento di salute mentale USL RM11, Rome, Italy
    Eur Arch Psychiatry Clin Neurosci 243:299-303. 1994
    In a series of 1007 consecutively admitted patients, 3 cases of neuroleptic malignant syndrome (NMS) were identified (0.3%)...
  22. ncbi Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine
    Thomas Paparrigopoulos
    Department of Psychiatry, Athens University Medical School, Eginition Hospital, Athens, Greece
    World J Biol Psychiatry 10:70-3. 2009
    ..abnormalities and shares many clinical, biological and treatment response features with the neuroleptic malignant syndrome (NMS), a rare adverse reaction to psychoactive medications...
  23. ncbi Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia
    Ashish Srivastava
    Institute of Psychiatry and Human Behaviour, Bambolim, Goa, India
    Psychiatry Clin Neurosci 63:119-21. 2009
    A case of a male patient with schizophrenic illness who developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine is reported...
  24. ncbi Neuroleptic malignant syndrome: case report and discussion
    Geethan J Chandran
    Department of General Surgery, University of Saskatchewan, Saskatoon, SK
    CMAJ 169:439-42. 2003
    We report a case involving an 81-tear-old man with schizoaffective disorder who presented with neuroleptic malignant syndrome (NMS) after an increase in his neuroleptic dose...
  25. ncbi Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication
    M Stotz
    Department of Anaesthesia, University of Basel Kantonsspital, CH 4031 Basel, Switzerland
    Br J Anaesth 93:868-71. 2004
    b>Neuroleptic malignant syndrome is a rare complication when using neuroleptic drugs...
  26. ncbi Possible neuroleptic malignant syndrome associated with paliperidone
    Harpreet S Duggal
    J Neuropsychiatry Clin Neurosci 19:477-8. 2007
  27. ncbi Neuroleptic malignant syndrome due to three atypical antipsychotics in a child
    Dong-Seon Chungh
    Division of Child and Adolescent Psychiatry, Department of Psychiatry, Seoul National University Bundang Hospital, Seoul, Korea
    J Psychopharmacol 19:422-5. 2005
    b>Neuroleptic Malignant Syndrome (NMS) is a rare, potentially fatal and idiosyncratic drug reaction...
  28. ncbi Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome
    Joseph W Y Lee
    Graylands Hospital and School of Psychiatry and Clinical Neurosciences, University of Western Australia, Australia
    Ann Clin Psychiatry 19:9-16. 2007
    This case series study examines the hypothesis that neuroleptic malignant syndrome (NMS) is a heterogeneous condition including catatonic variants and non-catatonic pathological reactions to antipsychotics.
  29. ncbi Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review
    Rachel Neuhut
    Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA
    J Child Adolesc Psychopharmacol 19:415-22. 2009
    b>Neuroleptic malignant syndrome (NMS) is a severe iatrogenic complication of treatment with antipsychotic medication...
  30. ncbi Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature
    Dallas P Seitz
    Department of Psychiatry, Queen s University, Kingston, Ontario, Canada
    Psychosomatics 50:8-15. 2009
    b>Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics.
  31. ncbi Neuroleptic malignant syndrome induced by atypical antipsychotics
    Debra K Farver
    South Dakota State University, South Dakota Human Services Center, PO Box 76, Yankton, SD 57078, USA
    Expert Opin Drug Saf 2:21-35. 2003
    A review of the English literature confirms that neuroleptic malignant syndrome (NMS) occurs with both traditional and atypical antipsychotic medications...
  32. ncbi Neuroleptic malignant syndrome with aripiprazole and lithium: a case report
    Syed Ali
    J Clin Psychopharmacol 26:434-6. 2006
  33. ncbi Clinical risk factors for neuroleptic malignant syndrome
    Domenico Berardi
    Institute of Psychiatry, Bologna University
    Hum Psychopharmacol 17:99-102. 2002
    Pharmacological risk factors for neuroleptic malignant syndrome (NMS) are better defined than clinical risk factors. We examined the psychopathological status preceding the onset of NMS in 20 patients...
  34. ncbi Neuroleptic malignant syndrome associated with ziprasidone in an adolescent
    Joseph Leibold
    Department of Emergency Medicine, Wright State University, Ohio, USA
    Clin Ther 26:1105-8. 2004
    BACKGROUND: Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal disorder characterized by fever, muscular rigidity, delirium, and autonomic instability...
  35. ncbi Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations
    Lara S Picard
    Division of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA
    Pharmacotherapy 28:530-5. 2008
    b>Neuroleptic malignant syndrome (NMS) is a serious and potentially fatal adverse effect of antipsychotic drugs. The diagnosis of NMS commonly requires core symptoms of hyperthermia and muscle rigidity...
  36. ncbi Neuroleptic Malignant Syndrome with ziprasidone
    Radhika G Murty
    J Clin Psychopharmacol 22:624-6. 2002
  37. ncbi Neuroleptic malignant syndrome precipitated by haloperidol following clozapine discontinuation
    D N Mendhekar
    Aust N Z J Psychiatry 39:947-8. 2005
  38. ncbi Genotype A1/A2 associated with neuroleptic malignant syndrome
    M Del Tacca
    Bipolar Disord 7:390-1. 2005
  39. ncbi Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents
    B Spivak
    Research Unit, Ness Ziona Government Psychiatric Hospital, Israel
    Int Clin Psychopharmacol 11:207-9. 1996
    b>Neuroleptic malignant syndrome (NMS) is a severe side-effect of neuroleptic treatment. It is usually related to hypodopaminergic activity...
  40. ncbi Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome
    R J Gurrera
    Department of Psychiatry, Harvard Medical School, Brockton West Roxbury DVA Medical Center, Brockton, MA 02301, USA
    Am J Psychiatry 156:169-80. 1999
    The author's goal was to develop a pathophysiological model for neuroleptic malignant syndrome with greater explanatory power than the alternative hypotheses of hypothalamic dopamine antagonism (elevated set point) and direct myotoxicity (..
  41. ncbi Recognizing neuroleptic malignant syndrome
    Patricia I Rosebush
    CMAJ 170:1645. 2004
  42. ncbi Olanzapine-associated neuroleptic malignant syndrome
    Vassilis P Kontaxakis
    Department of Psychiatry, Eginition Hospital, University of Athens, 74, Vas Sophias Avenue, 11528 Athens, Greece
    Prog Neuropsychopharmacol Biol Psychiatry 26:897-902. 2002
    b>Neuroleptic malignant syndrome (NMS) is an uncommon but serious idiosyncratic reaction associated with antipsychotic medication...
  43. ncbi Intrathecal baclofen withdrawal simulating neuroleptic malignant syndrome in a child with cerebral palsy
    L Samson-Fang
    Department of Pediatrics, University of Utah School of Medicine, Salt Lake City 84132, USA
    Dev Med Child Neurol 42:561-5. 2000
    ..His clinical course is compared to that of adults experiencing withdrawal from IBI and to neuroleptic malignant syndrome. If unrecognized, this disorder may have significant potential for morbidity and mortality...
  44. ncbi Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome
    D N Mendhekar
    J Neuropsychiatry Clin Neurosci 18:552-3. 2006
  45. ncbi Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome
    E Cem Atbasoglu
    J Clin Psychiatry 65:1724-5. 2004
  46. ncbi Neuroleptic malignant syndrome and clozapine withdrawal at the same time?
    Branimir Margetic
    Neuropsychiatric Hospital Dr Ivan Barbot, 44 317 Popovaca, Croatia
    Prog Neuropsychopharmacol Biol Psychiatry 29:145-7. 2005
    ..abrupt discontinuation of clozapine and haloperidol developed agitated and confused state resembling neuroleptic malignant syndrome (NMS) and clozapine withdrawal symptoms at the same time...
  47. ncbi Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome
    Debra L Stevens
    Oklahoma DHS Developmental Disabilities Services Division, Oklahoma City, OK 73125, USA
    Ann Pharmacother 42:1290-7. 2008
    To review the published reports of neuroleptic malignant syndrome (NMS) associated with the use of selective serotonin-reuptake inhibitors (SSRIs) and second-generation antipsychotics.
  48. ncbi Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment
    Murat Eren Ozen
    Department of Psychiatry, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
    World J Biol Psychiatry 8:42-4. 2007
    b>Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders. We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone...
  49. ncbi Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient
    R Bottlender
    Department of Psychiatry, Ludwig Maximilians University, Munich
    Pharmacopsychiatry 35:119-21. 2002
    b>Neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal complication of antipsychotic medication. The risk of developing NMS under atypical neuroleptics seems lower than under typical neuroleptics...
  50. ncbi Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases
    Paul E Croarkin
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Clin Psychiatry 69:1157-65. 2008
    To retrospectively examine published cases of neuroleptic malignant syndrome (NMS) in patients aged 18 and below who had been treated with atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and ..
  51. ncbi Neuroleptic malignant syndrome in cancer treatment
    Chiaki Kawanishi
    Department of Psychiatry, Yokohama City University School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama 236 0004, Japan
    Palliat Support Care 3:51-3. 2005
    OBJECTIVE: Neuroleptic malignant syndrome (NMS) is a life-threatening reaction to neuroleptics. Several prospective studies have reported NMS occurrence rates ranging from 0.07% to 2.2% of patients receiving neuroleptics...
  52. ncbi Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic
    Ibrahim Abu-Kishk
    Pediatric Intensive Care Unit, Assaf Harofeh Medical Center, Israel
    J Toxicol Clin Toxicol 42:921-5. 2004
    b>Neuroleptic malignant syndrome (NMS) is an uncommon potentially fatal side effect of neuroleptic drugs, characterized by movement disorder, altered mental status and autonomic instability...
  53. ncbi Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis
    Kenneth R Kaufman
    Department of Psychiatry, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    Ann Clin Psychiatry 18:201-4. 2006
    Serotonin syndrome (SS) and neuroleptic malignant syndrome (NMS) are medical emergencies associated with psychotropic administration...
  54. ncbi Managing an effective treatment for neuroleptic malignant syndrome
    Udo Reulbach
    Department of Psychiatry and Psychotherapy, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
    Crit Care 11:R4. 2007
    b>Neuroleptic malignant syndrome (NMS) is a rare, but sometimes fatal, adverse reaction to neuroleptics characterized principally by fever and rigor...
  55. ncbi Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy
    Neeraj Berry
    Department of Psychiatry, National Pharmacovigilance Centre, All India Institute of Medical Sciences, New Delhi, India
    Pharmacotherapy 23:255-9. 2003
    ..Classic neuroleptic malignant syndrome (NMS) was diagnosed...
  56. ncbi Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome
    A Suzuki
    Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036 8562, Japan
    Am J Psychiatry 158:1714-6. 2001
    The pathophysiology of neuroleptic malignant syndrome is mainly explained by a central hypodopaminergic state...
  57. ncbi A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole
    Orson P Rodriguez
    St Anthony Family Medicine Residency, Oklahoma City, Oklahoma, USA
    J Okla State Med Assoc 99:435-8. 2006
    b>Neuroleptic malignant syndrome (NMS) is a rare disorder seen most often in patients exposed to antipsychotic medications...
  58. ncbi Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge
    Nicola S Gray
    Department of Psychiatry, Allegheny General Hospital, Four Allegheny Center, 8th Floor, Pittsburgh, PA 15212 4772, USA
    Hum Psychopharmacol 19:205-7. 2004
    A case of neuroleptic malignant syndrome (NMS) in a patient with Parkinson's disease (PD) is presented. The syndrome was precipitated by the atypical antipsychotic, ziprasidone...
  59. ncbi Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene
    I Kishida
    Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan
    Mol Psychiatry 9:293-8. 2004
    A genetic predisposition to the development of neuroleptic malignant syndrome (NMS) has been suggested by clinical studies...
  60. ncbi Ziprasidone- and lithium-induced neuroleptic malignant syndrome
    Mary C Borovicka
    College of Pharmacy, University of Toledo, Toledo, OH, USA
    Ann Pharmacother 40:139-42. 2006
    To report a case of ziprasidone- and lithium-induced neuroleptic malignant syndrome (NMS).
  61. ncbi Clinical management of neuroleptic malignant syndrome
    V L Susman
    New York Presbyterian Hospital, Westchester Division, USA
    Psychiatr Q 72:325-36. 2001
    b>Neuroleptic malignant syndrome (NMS) continues to be an unpredictable and rare, but potentially fatal complication of antipsychotic medications...
  62. ncbi Case-control study of neuroleptic malignant syndrome
    P Sachdev
    School of Psychiatry, University of New South Wales, Australia
    Am J Psychiatry 154:1156-8. 1997
    The authors performed a case-control study of neuroleptic malignant syndrome to identify potential risk factors.
  63. ncbi Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy
    Chiaki Kawanishi
    Department of Psychiatry, Yokohama City University School of Medicine, Yokohama, Japan
    Am J Pharmacogenomics 3:89-95. 2003
    The pathogenetic mechanism of neuroleptic malignant syndrome (NMS), a potentially lethal adverse effect of antipsychotics, is not well understood...
  64. ncbi Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case report
    Akiko Kobayashi
    Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 30:1170-2. 2006
    ..The present report is the first to describe a DLB patient who developed neuroleptic malignant syndrome (NMS) induced by quetiapine, an atypical neuroleptic known to have relatively infrequent ..
  65. ncbi Neuroleptic malignant syndrome: a review
    A L Pelonero
    Department of Psychiatry at Virginia Commonwealth University Medical College of Virginia, Richmond 23298 0710, USA
    Psychiatr Serv 49:1163-72. 1998
    b>Neuroleptic malignant syndrome is an uncommon side effect of antipsychotic medications characterized by severe rigidity, tremor, fever, altered mental status, autonomic dysfunction, and elevated serum creatinine phosphokinase and white ..
  66. ncbi Possible neuroleptic malignant syndrome with aripiprazole and fluoxetine
    Harpreet S Duggal
    Am J Psychiatry 162:397-8. 2005
  67. ncbi Case study. Risperidone-Induced neuroleptic malignant syndrome in an adolescent
    A S Robb
    Department of Psychiatry and Behavioral Science, The Children s National Medical Center, Washington, DC 20010, USA
    J Child Adolesc Psychopharmacol 10:327-30. 2000
    b>Neuroleptic malignant syndrome (NMS) is a potentially fatal complication of neuroleptic therapy, characterized by fever, rigidity, mental status changes, and autonomic instability...
  68. ncbi Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease
    Y Sato
    Department of Neurology, Futase Social Insurance Hospital, Iizuka 820 0054, Japan
    J Neurol Neurosurg Psychiatry 74:574-6. 2003
    b>Neuroleptic malignant syndrome (NMS) is a dangerous complication in patients with Parkinson's disease (PD).
  69. ncbi [Life threatening neuroleptic malignant syndrome due to olanzapine]
    Andrea Kopf
    , ,
    Psychiatr Prax 30:279-82. 2003
    The frequency of neuroleptic malignant syndrome (NMS) after clozapine or olanzapine is low and often of non-serious nature. A 49 year-old female patient developed NMS 12 days after olanzapine re-exposure...
  70. ncbi Neuroleptic malignant syndrome following administration of risperidone and lithium
    James A Bourgeois
    J Clin Psychopharmacol 23:315-7. 2003
  71. ncbi Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly
    Ryan C W Hall
    Johns Hopkins Sinai Hospital, Department of Medicine, Baltimore, MD, USA
    South Med J 98:114-7. 2005
    ..After an extensive workup to rule out infection, the patient was diagnosed as having neuroleptic malignant syndrome (NMS)...
  72. ncbi [Olanzapine-associated neuroleptic malignant syndrome. A case report and favorable response to risperidone]
    E Lopez-Torres
    Actas Esp Psiquiatr 35:145-6. 2007
  73. ncbi Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia
    Ahmed Aboraya
    Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, USA
    W V Med J 98:63-5. 2002
    ..During this two-week period, this patient began to develop signs and symptoms of neuroleptic malignant syndrome (NMS)...
  74. ncbi Catatonia and neuroleptic malignant syndrome: two sides of a coin?
    E Vancaester
    Dept of Neurology, University Hospital Gent, Gent, Belgium
    Acta Neurol Belg 107:47-50. 2007
    ..Since catatonia shares a number of symptoms with the neuroleptic malignant syndrome (NMS) and similar treatments can be used in both conditions, it has also been suggested that NMS and ..
  75. ncbi Neuroleptic malignant syndrome and catatonia in a patient with dementia
    Dhiren Singh
    Aust N Z J Psychiatry 42:547-8. 2008
  76. ncbi [Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment]
    M Pezza
    Cattedra di Anestesia e Rianimazione, , Napoli, Italy
    Minerva Anestesiol 69:591-6. 2003
    ..The causes of rhabdomyolysis are usually traumatic and non-traumatic, such as neuroleptic malignant syndrome and rhabdomyolysis associated to septicemia...
  77. ncbi [The life threatening adverse effects of psychotropic drugs: a case report]
    Ahmet Tiryaki
    Kradeniz Teknik U Tip Fak, Psikiyatri AD Trabzon
    Turk Psikiyatri Derg 17:147-51. 2006
    b>Neuroleptic malignant syndrome (NMS) is a rare idiosyncratic reaction to antipsychotic drugs that is potentially fatal...
  78. ncbi Movement disorders and the treatment of schizophrenia
    John Ellard
    Balmoral Beach, NSW, Australia
    Australas Psychiatry 12:409. 2004
  79. ncbi Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia
    Max Fink
    Prog Neuropsychopharmacol Biol Psychiatry 30:1182-3; author reply 1184-5. 2006
  80. ncbi [Drug-induced neuroleptic malignant syndrome]
    Hiroaki Jitsuiki
    Nippon Naika Gakkai Zasshi 96:1627-33. 2007
  81. ncbi [Considerations in the combination of clozapine and benzodiazepines]
    R Rupprecht
    Klinik für Psychiatrie und Psychotherapie der Ludwig Maximilians Universität München, Munchen, Deutschland
    Nervenarzt 75:857-60. 2004
    ..Moreover, the formulation of such guidelines would help with forensic issues in case of serious adverse events occurring during this combination therapy...
  82. ncbi [Lethal catatonia and its differential diagnosis with the neuroleptic malignant syndrome]
    L Andreu Gimenez
    Rev Neurol 34:399-400. 2002
  83. ncbi Drug-induced catatonia
    Harpreet S Duggal
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O Hara St, Pennsylvania 15213, USA
    Drugs Today (Barc) 41:599-607. 2005
    ..This article attempts to review the available literature in this realm and integrate the information in an attempt to explore the epidemiology, etiology, mechanism and treatment of drug-induced catatonia...
  84. ncbi Toxic interaction between risperidone and clozapine: a case report
    Vassilis P Kontaxakis
    Department of Psychiatry, University of Athens, Eginition Hospital, Greece
    Prog Neuropsychopharmacol Biol Psychiatry 26:407-9. 2002
    ..of neurotoxicity, there are reports regarding various neurotoxic or idiosyncratic reactions including neuroleptic malignant syndrome (NMS)...
  85. ncbi Catatonia in psychiatric classification
    Filip Van Den Eede
    Am J Psychiatry 161:2327-8; author reply 2328. 2004
  86. ncbi Caution is still needed when prescribing atypical antipsychotics
    Stephen Carey
    Br J Hosp Med (Lond) 69:299. 2008
  87. ncbi Neuroleptic malignant syndrome associated with risperidone in a male with early-onset schizophrenia
    A Mane
    J Child Adolesc Psychopharmacol 15:844-5. 2005
  88. ncbi Genetic predisposition to neuroleptic malignant syndrome in siblings
    Marc Ziegenbein
    Ann Pharmacother 40:574-5. 2006
  89. ncbi [Neuroleptic malignant syndrome after 30 years treatment with clozapine: a rarely seen differential diagnosis on intensive care units]
    D Franzen
    Spital Zollikerberg, Medizinische Klinik, Zurich, Schweiz
    Anasthesiol Intensivmed Notfallmed Schmerzther 41:125-7. 2006
    The neuroleptic malignant syndrome (NMS) is a rare, but potentially lethal side effect of conventional and atypical antipsychotic drugs...
  90. ncbi [Neuroleptic malignant syndrome in users of risperidone]
    F Bonte-Mineur
    Ned Tijdschr Geneeskd 149:158-9; author reply 159. 2005
  91. ncbi [Neuroleptic malignant syndrome in users of risperidone]
    T van Bemmel
    Ned Tijdschr Geneeskd 149:608; author reply 608. 2005
  92. ncbi Comment: neuroleptic malignant syndrome associated with risperidone and fluvoxamine
    Geoffrey K Isbister
    Ann Pharmacother 36:1293; author reply 1294. 2002
  93. ncbi [Neuroleptic malignant syndrome in users of risperidone]
    J A Van Waarde
    Ned Tijdschr Geneeskd 149:156-7; author reply 157. 2005
  94. ncbi Neuroleptic malignant syndrome caused by combination of risperidone and lithium in a patient with multiple medical comorbidities
    Seyfullah Gorkem Kosehasanogullari
    Prog Neuropsychopharmacol Biol Psychiatry 31:1147-8. 2007
  95. ncbi Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrhea
    U Patel
    Division of Cardiology, Coney Island Hospital, New York, New York 11235, USA
    J Natl Med Assoc 94:279-82. 2002
    b>Neuroleptic malignant syndrome is a rare (incidence, 0.02%-3.2%) but dangerous complication following the use of neuroleptic drugs. When not promptly recognized, this disease carries a high mortality (10%-20%) and morbidity rate...
  96. ncbi Atypical neuroleptic malignant syndrome associated with olanzapine
    Roy R Reeves
    G V Sonny Montgomery Veterans Administration Medical Center, Jackson, Mississippi 39216, USA
    Pharmacotherapy 22:641-4. 2002
    b>Neuroleptic malignant syndrome (NMS) is a potentially life-threatening adverse effect of antipsychotic agents. It generally is characterized by fever, altered mental status, rigidity, and autonomic dysfunction...
  97. ncbi Olanzapine induced "typical" neuroleptic malignant syndrome
    Joseph S Goveas
    J Clin Psychopharmacol 23:101-2. 2003
  98. ncbi Neuroleptic malignant syndrome presenting with acute renal failure
    Harpreet S Duggal
    Prog Neuropsychopharmacol Biol Psychiatry 32:1074-5. 2008
  99. ncbi Neuroleptic malignant syndrome and low-dose olanzapine
    Hester Suh
    Am J Psychiatry 160:796. 2003
  100. ncbi Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy
    Debra L Stevens
    University of Oklahoma College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, USA
    Pharmacotherapy 28:403-5. 2008
    b>Neuroleptic malignant syndrome (NMS) is an idiosyncratic and uncommon but serious adverse effect that has been reported with both typical and atypical antipsychotic agents...
  101. ncbi Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients
    Jordi Casademont
    Muscle Research Unit, Internal Medicine Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    J Clin Psychopharmacol 27:284-8. 2007
    ..It remains to be established if this finding in a nontarget tissue for antipsychotics may account for the lower incidence of movement disorders observed in patients on atypical agents...

Research Grants9

  1. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  2. Ecstasy and the Dorsomedial Hypothalamus
    DANIEL RUSYNIAK; Fiscal Year: 2007
    ....
  3. Multidisciplinary Study of Social Behavior and Emotion in Frontotemporal Dementia
    Mario Mendez; Fiscal Year: 2009
    ..This application combines many specialists to study disturbed social behavior in frontotemporal dementia. The results of the project can clarify how social behavior is altered by mental disorders or brain diseases. ..
  4. Multidisciplinary Study of Social Behavior and Emotion in Frontotemporal Dementia
    MARIO FERNANDO MENDEZ; Fiscal Year: 2010
    ..This application combines many specialists to study disturbed social behavior in frontotemporal dementia. The results of the project can clarify how social behavior is altered by mental disorders or brain diseases. ..
  5. CNS circuitry and receptors mediating the effects of MDMA
    Daniel E Rusyniak; Fiscal Year: 2010
    ..of sympathetic, somatic motor and neuroendocrine systems: serotonin syndrome;cocaine toxicity, neuroleptic malignant syndrome;dysautonomia from brain injury, and heat stroke...